Apimeds Pharmaceuticals US APUS
NYSE APUS
$4.16 -0.23 (-5.21%)
At close: Aug 20, 2026 · 11:16 AM UTC

Apimeds Pharmaceuticals US (APUS) Net Income towards Common Stockholders (2024 - 2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Net Income towards Common Stockholders came in at -$7.3 million in Q4 2025, down 1797.17% YoY from $429099.8 in Q4 2024, and down 305.91% on a QoQ basis from -$1.8 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Net Income towards Common Stockholders (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 2 years of Net Income towards Common Stockholders data on file, last reported at -$7.3 million in Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 1797.17% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.2 million (down 730.98% YoY) and the FY2025 annual result came in at -$14.5 million, down 498.81% from the prior year.
  • Net Income towards Common Stockholders fell to -$7.3 million in Q4 2025, from -$1.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$296473.0 in Q1 2024 to a low of -$7.3 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 44.05 Bn 43.08 Bn - -
2 Teva Pharmaceutical Industries 43.39 Bn 39.74 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.86 Bn 30.18 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.78 Bn 22.99 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 22.25 Bn 19.59 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.74 Bn 17.85 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.58 Bn 15.19 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 11.92 Bn 11.39 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.16 Bn 9.99 Bn - -
10 Apimeds Pharmaceuticals US 7.12 Mn 7.12 Mn - -9.48 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.28 Mn
Sep 30, 2025 -1.79 Mn
Jun 30, 2025 -2.67 Mn
Mar 31, 2025 -402,397.00
Dec 31, 2024 -383,864.00
Sep 30, 2024 -332,521.00
Jun 30, 2024 -449,363.00
Mar 31, 2024 -296,473.00